KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals has reported Total Non-Current Liabilities over the past 9 years, most recently at $2.8 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $2.8 billion for Q4 2025, up 15.5% from a year ago — trailing twelve months through Dec 2025 was $2.8 billion (up 15.5% YoY), and the annual figure for FY2025 was $2.8 billion, up 15.5%.
  • Total Non-Current Liabilities for Q4 2025 was $2.8 billion at Amneal Pharmaceuticals, roughly flat from $2.8 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AMRX hit a ceiling of $2.9 billion in Q2 2021 and a floor of $2.3 billion in Q1 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $2.8 billion (2023), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 12.44% in 2024 and later grew 15.86% in 2025.
  • Amneal Pharmaceuticals' Total Non-Current Liabilities stood at $2.9 billion in 2021, then dropped by 1.42% to $2.8 billion in 2022, then decreased by 9.62% to $2.6 billion in 2023, then fell by 5.79% to $2.4 billion in 2024, then rose by 15.5% to $2.8 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $2.8 billion (Q4 2025), $2.8 billion (Q3 2025), and $2.4 billion (Q2 2025) per Business Quant data.